Altered fecal bile acid composition in active ulcerative colitis.
Bile acids
Cholic acid
Crohn´s Disease
Deoxycholic acid
Fecal calprotectin
Ulcerative Colitis
Journal
Lipids in health and disease
ISSN: 1476-511X
Titre abrégé: Lipids Health Dis
Pays: England
ID NLM: 101147696
Informations de publication
Date de publication:
18 Nov 2023
18 Nov 2023
Historique:
received:
10
10
2023
accepted:
13
11
2023
medline:
20
11
2023
pubmed:
19
11
2023
entrez:
19
11
2023
Statut:
epublish
Résumé
Disturbed bile acid homeostasis associated with a rise of primary and a decline of secondary bile acids is a consistent finding in inflammatory bowel diseases (IBDs). Whether fecal bile acids may emerge as biomarkers for IBD diagnosis and disease severity is less clear. Our study aimed to identify associations of 18 fecal bile acid species with IBD entity and disease activity. Stool samples of 62 IBD patients and 17 controls were collected. Eighteen fecal bile acid species were quantified by LC-MS/MS using stable isotope dilution. Lipid levels normalized to a dry weight of the fecal homogenates and ratios of single bile acid species to total bile acid levels were used for calculations. IBD patients exhibited altered primary and secondary bile acid ratios in stool, with notable distinctions between ulcerative colitis (UC) compared to Crohn's disease (CD) and healthy controls. Fecal calprotectin was negatively correlated with glycolithocholic acid (GLCA) and hyodeoxycholic acid (HDCA) in UC. These bile acids were reduced in stool of UC patients with fecal calprotectin levels > 500 µg/g compared to UC patients with low calprotectin levels. Moreover, negative associations of six secondary bile acids with C-reactive protein (CRP) existed in UC. In CD patients, fecal bile acids did not correlate with CRP or fecal calprotectin. Diarrhoea is common in IBD, and UC patients with diarrhoea had reduced deoxycholic acid (DCA), glycine conjugated DCA (GDCA) and lithocholic acid in stool in contrast to patients with normal stool consistency. Fecal bile acid levels were not associated with diarrhoea in CD patients. UC patients treated with mesalazine had increased levels of fecal GDCA whereas no such changes were observed in CD patients. Bile acid levels of CD and UC patients treated with biologicals or corticosteroids did not change. Relative levels of GHDCA (specificity: 79%, sensitivity: 67%) and glycochenodeoxycholic acid (specificity: 74%, sensitivity: 63%) were the most specific to distinguish UC from CD. Disrupted fecal bile acid homeostasis is associated with disease severity and disease symptoms in UC but not in CD, potentially aiding in distinguishing IBD subtypes and classifying the pathophysiology of diarrhoea in UC.
Sections du résumé
BACKGROUND
BACKGROUND
Disturbed bile acid homeostasis associated with a rise of primary and a decline of secondary bile acids is a consistent finding in inflammatory bowel diseases (IBDs). Whether fecal bile acids may emerge as biomarkers for IBD diagnosis and disease severity is less clear. Our study aimed to identify associations of 18 fecal bile acid species with IBD entity and disease activity.
METHODS
METHODS
Stool samples of 62 IBD patients and 17 controls were collected. Eighteen fecal bile acid species were quantified by LC-MS/MS using stable isotope dilution. Lipid levels normalized to a dry weight of the fecal homogenates and ratios of single bile acid species to total bile acid levels were used for calculations.
RESULTS
RESULTS
IBD patients exhibited altered primary and secondary bile acid ratios in stool, with notable distinctions between ulcerative colitis (UC) compared to Crohn's disease (CD) and healthy controls. Fecal calprotectin was negatively correlated with glycolithocholic acid (GLCA) and hyodeoxycholic acid (HDCA) in UC. These bile acids were reduced in stool of UC patients with fecal calprotectin levels > 500 µg/g compared to UC patients with low calprotectin levels. Moreover, negative associations of six secondary bile acids with C-reactive protein (CRP) existed in UC. In CD patients, fecal bile acids did not correlate with CRP or fecal calprotectin. Diarrhoea is common in IBD, and UC patients with diarrhoea had reduced deoxycholic acid (DCA), glycine conjugated DCA (GDCA) and lithocholic acid in stool in contrast to patients with normal stool consistency. Fecal bile acid levels were not associated with diarrhoea in CD patients. UC patients treated with mesalazine had increased levels of fecal GDCA whereas no such changes were observed in CD patients. Bile acid levels of CD and UC patients treated with biologicals or corticosteroids did not change. Relative levels of GHDCA (specificity: 79%, sensitivity: 67%) and glycochenodeoxycholic acid (specificity: 74%, sensitivity: 63%) were the most specific to distinguish UC from CD.
CONCLUSION
CONCLUSIONS
Disrupted fecal bile acid homeostasis is associated with disease severity and disease symptoms in UC but not in CD, potentially aiding in distinguishing IBD subtypes and classifying the pathophysiology of diarrhoea in UC.
Identifiants
pubmed: 37980492
doi: 10.1186/s12944-023-01971-4
pii: 10.1186/s12944-023-01971-4
pmc: PMC10656844
doi:
Substances chimiques
Bile Acids and Salts
0
Biomarkers
0
C-Reactive Protein
9007-41-4
Leukocyte L1 Antigen Complex
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
199Informations de copyright
© 2023. The Author(s).
Références
Physiol Rep. 2020 Mar;8(5):e14358
pubmed: 32170845
Front Nutr. 2022 Jan 21;8:818902
pubmed: 35127797
World J Gastroenterol. 2021 Jun 28;27(24):3609-3629
pubmed: 34239273
Cells. 2022 Mar 05;11(5):
pubmed: 35269523
Ann Gastroenterol. 2018 May-Jun;31(3):266-272
pubmed: 29720851
Ann N Y Acad Sci. 2006 Aug;1072:365-78
pubmed: 17057217
Digestion. 2023;104(1):30-41
pubmed: 36404714
Clin Exp Gastroenterol. 2019 Jan 10;12:9-19
pubmed: 30666146
Gut. 1971 Aug;12(8):632-5
pubmed: 18668831
J Hepatol. 2014 Aug;61(2):351-7
pubmed: 24681341
J Crohns Colitis. 2020 Sep 7;14(8):1090-1102
pubmed: 32119090
Front Microbiol. 2023 Feb 23;14:1107976
pubmed: 36910207
Gut. 2013 Apr;62(4):531-9
pubmed: 22993202
Gut. 2004 Jan;53(1):10-1
pubmed: 14684568
J Thorac Oncol. 2010 Sep;5(9):1315-6
pubmed: 20736804
Gastroenterology. 2015 Oct;149(5):1275-1285.e2
pubmed: 26166315
Biochem Pharmacol. 2012 Oct 15;84(8):1000-6
pubmed: 22820246
Anal Chem. 2016 Nov 15;88(22):10957-10961
pubmed: 27736066
Microorganisms. 2021 Apr 30;9(5):
pubmed: 33946482
Br J Gen Pract. 2018 Oct;68(675):497-498
pubmed: 30262630
Dig Liver Dis. 2016 Jul;48(7):771-9
pubmed: 27133208
Am J Gastroenterol. 2007 Sep;102(9):2058-69
pubmed: 17561966
World J Clin Cases. 2022 Oct 6;10(28):9985-10003
pubmed: 36246826
Gastroenterol Rep (Oxf). 2022 Jun 30;10:goac029
pubmed: 35785264
Gastroenterology. 2006 Aug;131(2):554-67
pubmed: 16890608
Front Med (Lausanne). 2022 Jul 11;9:920732
pubmed: 35911403
J Hepatol. 2020 Mar;72(3):558-577
pubmed: 31622696
Nat Microbiol. 2019 Feb;4(2):293-305
pubmed: 30531976
J Crohns Colitis. 2022 Nov 23;16(11):1777-1790
pubmed: 35679608
Dis Mon. 2019 Dec;65(12):100851
pubmed: 30837080
Cureus. 2023 Aug 24;15(8):e44055
pubmed: 37638277
Gastroenterol Clin North Am. 2012 Sep;41(3):651-75
pubmed: 22917170
Biomedicines. 2022 Jun 24;10(7):
pubmed: 35884797
J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Nov 15;877(30):3920-5
pubmed: 19819765
Sci Rep. 2020 Nov 24;10(1):20436
pubmed: 33235223
World J Gastroenterol. 2015 Jan 7;21(1):21-46
pubmed: 25574078
J Crohns Colitis. 2019 Mar 26;13(3):273-284
pubmed: 30137278
World J Gastroenterol. 2009 Jul 7;15(25):3134-41
pubmed: 19575493
Front Immunol. 2021 Jun 03;12:691480
pubmed: 34149734
Gut. 2006 Mar;55(3):426-31
pubmed: 16474109
Front Physiol. 2020 Jun 12;11:564
pubmed: 32595517
Front Immunol. 2022 Dec 07;13:1021924
pubmed: 36569849
Gut. 2021 Oct;70(10):1978-1988
pubmed: 34145045
Dis Mon. 2018 Feb;64(2):20-57
pubmed: 28826742
Gastroenterol Rep (Oxf). 2022 Jun 08;10:goac025
pubmed: 35692303
Metabolites. 2022 Aug 05;12(8):
pubmed: 36005595